Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F20%3AN0000073" target="_blank" >RIV/00098892:_____/20:N0000073 - isvavai.cz</a>
Result on the web
<a href="https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1789624?scroll=top&needAccess=true" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1789624?scroll=top&needAccess=true</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/10428194.2020.1789624" target="_blank" >10.1080/10428194.2020.1789624</a>
Alternative languages
Result language
angličtina
Original language name
Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT
Original language description
The purpose of this study was to analyze the results of second autologous hematopoietic stem cell transplantation (ASCT2) for patients with relapsed/refractory Hodgkin lymphoma (HL) after a first transplantation (ASCT1). Outcomes for 56 patients receiving an ASCT2 registered in the EBMT database were analyzed. The 4-year cumulative incidences of non-relapse mortality and disease relapse/progression were 5% and 67%, respectively. The 4-year overall survival (OS) and progression-free survival (PFS) were 62% and 28%. In univariate analysis, relapse of HL within 12 months of ASCT1 was associated with a worse OS (35% versus 76%,p = 0.01) and PFS (19% versus 29%,p = 0.059). Chemosensitivity at ASCT2 predicted better outcomes (4-year OS 72% versus 29%,p = 0.002; PFS 31% versus 12%,p = 0.015). This series shows that ASCT2 is a safe procedure and a relatively effective option for patients with late relapses after ASCT1 and with chemosensitive disease who are not eligible for an allogeneic transplant.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Leukemia & Lymphoma
ISSN
1042-8194
e-ISSN
1029-2403
Volume of the periodical
61
Issue of the periodical within the volume
12
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
2915-2922
UT code for WoS article
000547711700001
EID of the result in the Scopus database
2-s2.0-85087897461